Landmark Trials of Intravenous Iron in Heart Failure with Iron Deficiency
The three landmark trials establishing intravenous iron therapy for iron-deficient heart failure patients are FAIR-HF (2009), CONFIRM-HF (2015), and IRONMAN (2022), with the most recent comprehensive evidence from FAIR-HF2 (2024) demonstrating sustained cardiovascular benefit. 1, 2, 3, 4
Core Landmark Trials
FAIR-HF (2009)
- Design: Multicenter, randomized, double-blind, placebo-controlled phase III trial
- Population: 459 ambulatory patients with chronic HF and iron deficiency (ferritin <100 ng/mL or 100-300 ng/mL with transferrin saturation <20%), with or without anemia
- Intervention: Ferric carboxymaltose (FCM) 200 mg weekly until iron repletion, then 200 mg monthly
- Duration: 24 weeks
- Primary Endpoints: Patient Global Assessment (PGA) and NYHA functional class
- Key Results:
- 50% receiving FCM reported being much or moderately improved vs. 28% with placebo
- 47% achieved NYHA class I or II vs. 30% with placebo
- Significant improvement in 6-minute walk test distance
- Benefits seen in both anemic AND non-anemic patients 1
CONFIRM-HF (2015)
- Design: Multicenter, double-blind, placebo-controlled trial
- Population: 304 ambulatory symptomatic patients with CHF, LVEF ≤45%, elevated natriuretic peptides, and iron deficiency
- Intervention: FCM vs. placebo for 52 weeks
- Primary Endpoint: Change in 6-minute walk test distance at week 24
- Key Results:
- Significantly prolonged 6-minute walk distance at week 24 (sustained to week 52)
- Consistent improvement in NYHA class, PGA, quality of life, and fatigue scores
- Reduced risk of HF hospitalizations (secondary endpoint analysis)
- Treatment effect consistent across all subgroups 1
IRONMAN (2022)
- Design: Large randomized controlled trial
- Population: 1,137 patients with HF, ejection fraction ≤45%, and iron deficiency (ferritin <100 µg/L or TSAT <20%)
- Intervention: Intravenous ferric derisomaltose (FDI) vs. usual care
- Key Findings:
- Greater hemoglobin rise with lower baseline TSAT and more severe anemia
- Patients with TSAT <20% (especially with ferritin ≥100 µg/L) showed greater absolute reductions in events
- Absence of anemia or TSAT ≥20% associated with lower event rates and less benefit from IV iron 5
Additional Important Trials
FERRIC-HF (2008)
- Design: Multicenter, randomized, single-blind study
- Population: 35 patients with CHF and iron deficiency anemia
- Intervention: Iron sucrose 200 mg weekly until ferritin >500 ng/mL, then 200 mg monthly for 16 weeks
- Primary Endpoint: Change in absolute peak VO2
- Results: Improved exercise capacity and symptoms, with more pronounced benefits in anemic patients 1
AFFIRM-AHF, HEART-FID, and FAIR-HF2
These more recent trials (included in 2024-2025 meta-analyses) provide additional evidence for cardiovascular outcomes 4
Most Recent Meta-Analytic Evidence (2024-2025)
The 2025 Nature Medicine meta-analysis of 6 trials (7,175 patients) including FAIR-HF2 provides the strongest current evidence:
- Composite endpoint (recurrent HF hospitalizations + CV mortality) at 12 months: RR 0.72 [95% CI 0.55-0.89]
- Recurrent HF hospitalizations at 12 months: RR 0.69 [95% CI 0.48-0.88]
- CV mortality at 12 months: HR 0.80 [95% CI 0.61-1.03]
- All-cause mortality at 12 months: HR 0.82 [95% CI 0.65-1.03]
- Treatment effects greatest in first year when IV iron doses highest 4
Guideline Recommendations Based on These Trials
2017 ACC/AHA/HFSA Guidelines
Class IIb recommendation (Level B-R): In patients with NYHA class II-III HF and iron deficiency (ferritin <100 ng/mL or 100-300 ng/mL with TSAT <20%), intravenous iron replacement might be reasonable to improve functional status and quality of life 2, 3
2016 ESC Guidelines
Class IIa recommendation: IV ferric carboxymaltose should be considered in symptomatic patients with HFrEF and iron deficiency to alleviate HF symptoms and improve exercise capacity and quality of life 6
2022 AHA/ACC/HFSA Guidelines
Reinforces that iron deficiency is uniquely associated with reduced exercise capacity, and IV iron repletion improves exercise capacity and quality of life based on FAIR-HF and CONFIRM-HF trials 7
Critical Clinical Pearls
Iron deficiency definition used across trials: Ferritin <100 ng/mL OR ferritin 100-300 ng/mL with transferrin saturation <20% 2, 3, 6
Oral iron is inadequate: The IRONOUT HF trial showed no improvement with oral iron supplementation due to poor absorption in HF patients 7
Benefits independent of anemia: Improvements seen in both anemic and non-anemic iron-deficient patients 1
Safety profile: No differences in death rates or adverse events compared to placebo across trials, though trials were underpowered for mortality endpoints 1
Optimal patient selection: Recent evidence suggests greatest benefit in patients with TSAT <20%, especially when ferritin ≥100 µg/L 5